Scarica l'app Stockscreener
0.595
9.83%
-0.0649
Dopo l'orario di chiusura:
.59
-0.005
-0.84%
Precedente Chiudi:
$0.6599
Aprire:
$0.6575
Volume 24 ore:
440.55K
Relative Volume:
2.33
Capitalizzazione di mercato:
$9.80M
Reddito:
$4.03M
Utile/perdita netta:
$24.32M
Rapporto P/E:
-0.1383
EPS:
-4.3008
Flusso di cassa netto:
$-45.76M
1 W Prestazione:
-20.67%
1M Prestazione:
-9.85%
6M Prestazione:
-53.15%
1 anno Prestazione:
-73.44%
Intervallo 1D:
$0.59
$0.6575
Intervallo di 1 settimana:
$0.59
$0.7443
Portata 52W:
$0.5719
$2.4299
Pavmed Inc Stock (PAVM) Company Profile
Nome
Pavmed Inc
Settore
Industria
Telefono
(212) 949-4319
Indirizzo
360 MADISON AVENUE, NEW YORK, NY
Confronta PAVM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PAVM
Pavmed Inc
|
0.595 | 9.80M | 4.03M | 24.32M | -45.76M | -4.3008 |
|
ABT
Abbott Laboratories
|
124.44 | 215.82B | 41.95B | 13.40B | 6.35B | 7.65 |
|
SYK
Stryker Corp
|
345.80 | 142.48B | 22.60B | 2.99B | 3.49B | 7.76 |
|
BSX
Boston Scientific Corp
|
89.70 | 132.67B | 16.75B | 1.85B | 2.37B | 1.25 |
|
MDT
Medtronic Plc
|
82.88 | 106.28B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
69.36 | 40.63B | 5.72B | 4.17B | 259.90M | 6.97 |
Pavmed Inc Stock (PAVM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-03-30 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-11-05 | Iniziato | Ascendiant Capital Markets | Buy |
| 2018-06-28 | Iniziato | Maxim Group | Buy |
Pavmed Inc Borsa (PAVM) Ultime notizie
Lucid Diagnostics to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference - BioSpace
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
PAVmed outlines strategic milestones for 2025, including Veris implantable device submission - MSN
Pavmed’s Strategic Growth and Financial Challenges - MSN
PAVmed Inc. (NASDAQ:PAVM) Q4 2024 Earnings Call Transcript - Insider Monkey
Lucid Diagnostics Launches "Embrace the Future" Campaign Showcasing EsoCheck's Groundbreaking Collect+Protect Esophageal Cell Collection Technology - PR Newswire
PAVmed Inc (PAVM) Q4 2024 Earnings Call Highlights: Strategic Growth and Financial Stability - Yahoo
PAVmed Inc (PAVM) Q4 2024 Earnings Call Highlights: Strategic Gr - GuruFocus.com
PAVmed Reports Strong Q4 Results and Strategic Progress - TipRanks
Earnings call transcript: PAVmed Q4 2024 reports net income boost - Investing.com India
Earnings call transcript: PAVmed Q4 2024 reports net income boost By Investing.com - Investing.com South Africa
PAVmed Inc Surpasses Q4 2024 Revenue Estimates with $1.2 Million, Driven by Record EsoGuard Test Volume - GuruFocus
PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results - Placera.se
PAVmed Inc reports results for the quarter ended December 31Earnings Summary - TradingView
PAVmed Achieves Triple Win: Record Tests, Insurance Coverage, Positive Income - Stock Titan
Lucid Diagnostics Reports Strong Growth and Future Plans - TipRanks
Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results - PR Newswire
Lucid Diagnostics Announces Updated National Comprehensive Cancer Network® (NCCN) Guidelines Now Include Esophageal Precancer Screening - The Malaysian Reserve
Lucid Diagnostics Announces Updated National Comprehensive Cance - GuruFocus
Major Breakthrough: NCCN Backs New Esophageal Cancer Testing Method, Insurance Coverage Expected to Expand - Stock Titan
Lucid Diagnostics' ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication - BioSpace
Lucid Diagnostics' ENVET-BE Clinical Utility Study of EsoGuard® - GuruFocus.com
Clinical Study: New EsoGuard Test Detects Esophageal Cancer Risk 140% More Effectively - StockTitan
Lucid Diagnostics Secures First Positive Commercial Insurance Coverage Policy for its EsoGuard® Esophageal DNA Test - The Malaysian Reserve
Lucid Diagnostics Secures First Positive Commercial Insurance Coverage Policy for its EsoGuard® Esophageal DNA Test – Company AnnouncementFT.com - Financial Times
Major Breakthrough: Lucid Diagnostics Secures Game-Changing Insurance Coverage for Cancer Test - Stock Titan
Lucid Diagnostics Executes First Concierge Medicine Contract wit - GuruFocus.com
Lucid Diagnostics Regains Compliance with Nasdaq Minimum Bid Pri - GuruFocus.com
PAVmed to Hold a Business Update Conference Call and Webcast on March 25, 2025 - Longview News-Journal
PAVmed CEO to Reveal Growth Strategy and Q4 Results in Upcoming Investor Call - Stock Titan
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 24, 2025 - BioSpace
Midtown company tells investors esophageal pre-cancer screening should be an easier pill to swallow - Crain's New York Business
PAVmed, Inc. to Host Earnings Call - ACCESS Newswire
Lucid Diagnostics Announces Closing of $15.3 Million Registered Direct Offering - BioSpace
Lucid Diagnostics secures $15.3 million in stock offering By Investing.com - Investing.com Australia
Lucid Diagnostics secures $15.3 million in stock offering - Investing.com India
Lucid Diagnostics secures $15.3 million in stock sale By Investing.com - Investing.com Australia
Lucid Diagnostics Announces $15.3 Million Registered Direct Offering - The Eastern Progress Online
SEC Form 424B5 filed by Lucid Diagnostics Inc. - Quantisnow
Lucid Diagnostics Raises $15.3 Million in Stock Offering - TipRanks
Insulet (NASDAQ:PODD) & PAVmed (NASDAQ:PAVM) Head-To-Head Review - Defense World
Lucid Diagnostics Announces $15.3 Million Registered Direct Offe - GuruFocus.com
Lucid Diagnostics ends "at the market" equity offering By Investing.com - Investing.com South Africa
Lucid Diagnostics ends "at the market" equity offering - Investing.com India
Lucid Diagnostics secures $15.3 million in stock sale - Investing.com
PAVmed Inc. (NASDAQ:PAVM) Short Interest Update - Defense World
Tasso Partners Reports 18.9% Passive Stake In PAVmed As Of Feb 21SEC Filing - Marketscreener.com
Pavmed Inc Azioni (PAVM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
7.46%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):